PT Kalbe Farma Tbk.

Jakarta Stock Exchange KLBF.JK

PT Kalbe Farma Tbk. Net Income for the year ending December 31, 2023: USD 179.84 M

PT Kalbe Farma Tbk. Net Income is USD 179.84 M for the year ending December 31, 2023, a -16.92% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.
  • PT Kalbe Farma Tbk. Net Income for the year ending December 31, 2022 was USD 216.46 M, a -2.87% change year over year.
  • PT Kalbe Farma Tbk. Net Income for the year ending December 31, 2021 was USD 222.85 M, a 16.48% change year over year.
  • PT Kalbe Farma Tbk. Net Income for the year ending December 31, 2020 was USD 191.33 M, a 6.01% change year over year.
  • PT Kalbe Farma Tbk. Net Income for the year ending December 31, 2019 was USD 180.49 M, a 6.46% change year over year.
Key data
Date Net Income EPS (Diluted) Shares (Diluted, Weighted) Net Income Margin
Market news
Loading...
Jakarta Stock Exchange: KLBF.JK

PT Kalbe Farma Tbk.

CEO Mr. . Vidjongtius
IPO Date Dec. 15, 2003
Location Indonesia
Headquarters Gedung KALBE
Employees 12,924
Sector Health Care
Industries
Description

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

Similar companies

INDF.JK

PT Indofood Sukses Makmur Tbk

USD 0.46

-2.13%

SMGR.JK

PT Semen Indonesia (Persero) Tbk

USD 0.17

-4.34%

UNVR.JK

PT Unilever Indonesia Tbk

USD 0.11

1.94%

ASII.JK

PT Astra International Tbk

USD 0.29

0.47%

UNTR.JK

PT United Tractors Tbk

USD 1.56

0.87%

StockViz Staff

January 15, 2025

Any question? Send us an email